Apex Labs gets govt nod to CleVira as Covid supportive drug
Advertisement
Chennai: City based pharma company Apex Laboratories will take the doctor's prescription route for its oral antiviral CleVira tablet that got the Central government's approval as a supporting measure for mild to moderate condition of Covid-19, a senior official said.
Apex Laboratories said it has got the approval from the Ministry of Ayush for its antiviral drug Clevira as a supporting measure for mild to moderate condition of Covid-19.
The company said this is the first of its kind approval in India through various stages of scrutiny at The Central Council for Research in Ayurvedic Sciences and Interdisciplinary Technical Review Committee.
According to the official, the company will position this as a doctor prescribed drug and not as an over-the-counter sales drug.
The company said a phase III Clinical trial was carried out in Government Medical College Omandurar Government Estate Chennai with Tamil Nadu government's approval.
The trial outcomes revealed that Clevira has shown 86 per cent recovery rate on fifty day of treatment in mild to moderate Covid-19 cases.
The official said enquiries from the medical practitioner world have started for CleVira as a medicine for Covid-19 following the approval from the Ministry of Ayush.
The company's flagship product is Zincovit which is in good demand from corporate hospitals for Covid-19. Apex Laboratories is also into dermatology, pain management, anti-infectives, anti-viral, nutraceuticals and herbal products.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.